THROMBOLYTIC THERAPY
THROMBOLYTIC THERAPY
复制标题
DOI：
10.1093/oxfordjournals.bmb.a070337
复制
发表时间：
1964-01-01
影响因子：
6.7
通讯作者：
MCNICOL, GP
中科院分区：
文献类型：
--
作者：
DOUGLAS, AS;MCNICOL, GP
最成功的血栓溶解酶是通过产生纤溶酶原活化而起作用的那些。目前的许多知识是通过使用链激酶获得的，因此前面的描述主要涉及这种激活剂。然而，在接下来的几年里，尿激酶可能会取代链激酶成为首选酶。输注激活剂后的生化研究扩展了对纤溶酶原-纤溶酶系统的理解，尽管存在困难，溶栓治疗仍显示出相当大的前景。应当理解，这不是血栓形成问题的最终答案，血栓形成问题必须等待真正的病因学方法。
The most successful thrombolytic enzymes are those which act by producing plasminogen activation. Much of the current knowledge has been gained by the use of streptokinase and therefore the preceding description is largely concerned with this activator. It may be, however, that the next few years will see urokinase replacing streptokinase as the enzyme of choice. Biochemical studies following infusion of activator have extended understanding of the plasminogen-plasmin system, and thrombolytic therapy, despite recognized difficulties, has shown considerable promise. It is appreciated that this is not the final answer to the problems of thrombosis, which must await a truly etiological approach.